Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and Reduce Symptoms of Gastric Reflux and Hyperacidity.
The investigators will include patients with gastroesophageal reflux disease and heartburn (more than 3 weekly episodes of heartburn for at least 4 consecutive weeks) not related to medication intake and don't use proton pump blockers or H2-receptor antagonists.
This is a multicentre clinical trial with two-phase design:
Phase I: A double-blind, randomised, placebo-controlled clinical trial to assess the efficacy and rapidity of action of the medical device to reduce clinical symptoms of gastric reflux and hyperacidity under normal conditions of use. This phase I will be performed in primary care clinics.
Phase II: A non-comparative, non-controlled clinical trial to objectively assess, using continuous pH monitoring, the magnitude and rapidity to control gastric and oesophageal pH after taking the product. This phase II will be performed at the Department of Gastroenterology of Medic Center.
The study will begin with the baseline visit (day 0) in which the inclusion and exclusion criteria will be confirmed, the signing of informed consent will be obtained, GERD-Q Questionnaire will be done and treatment will be prescribed, followed by a home recording where patients will record data on episodes of acidity and heartburn occuring during the follow-up week. A face-to-face visit will be at 7 days after to recollect information about total number of daytime and nighttime episodes of acidity/heartburn since the previous visit and repeat the GERD-Q Questionnaire.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention (Antacid) | Active Comparator | An Antacid, a CE marked medical device under normal conditions of use. Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet) Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day. |
|
| Control | Placebo Comparator | The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers. Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antacid | Device | The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Intensity of acidity/heartburn | Change in intensity of acidity/heartburn before and after taking the treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable) | At the beginning and at the end of treatment, an average of 7±1 days in patients |
| Time from treatment intake to resolution or maximum decrease in acidity/heartburn | Change in time from treatment intake to resolution or maximum decrease in acidity/heartburn as assessed by the patient using a 3-point Likert scale (<1 minute, 1-5 minutes, >5 minutes) | At the beginning and at the end of treatment, an average of 7±1 days in patients |
| Time elapsed between product intake and intragastric pH > 4 | Change in minutes of the time elapsed between product intake and intragastric pH > 4 | Baseline visit |
| Time with intragastric pH > 4 for 20 minutes before and after product intake | Total time in minutes of the time in intragastric pH > 4 for 20 minutes before and after product intake | Baseline visit |
| Measure | Description | Time Frame |
|---|---|---|
| Demographic data | Sex, ethnicity and age data of patients | Baseline visit |
| Time of tablet duration in the mouth before complete dissolution | Change in time of tablet duration in the mouth before complete dissolution, assessed using a 4-point Likert scale (< 1 minute, 1-3 minutes, 3-5 min, >5 minutes) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anna Fortuny | Contact | +34 938 630 311 | anna.fortuny@uriach.com | |
| Montse Vidal, Ph | Contact | +34 663825890 | montsevidal@crossdata.es |
| Name | Affiliation | Role |
|---|---|---|
| Oriol Armengol, Ph | Primary Health Center Poblenou, Barcelona, Spain | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oriol Armengol | Recruiting | Barcelona | 08008 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005764 | Gastroesophageal Reflux |
| D013035 | Spasm |
| ID | Term |
|---|---|
| D015154 | Esophageal Motility Disorders |
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
Clinical trial with CE marked medical device under normal conditions of use.
Not provided
Not provided
Not provided
| Control | Other | The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely. |
|
| At the beginning and at the end of treatment, an average of 7±1 days in patients |
| Number of daytime and nightime episodes of acidity/heartburn | Change in number of daytime and nightime episodes of acidity/heartburn (information recorded in the Patient Diary) | An average of 7±1 days in patients |
| Intensity of reflux before and after treatment | Change in intensity of reflux before and after treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable) | At the beginning and at the end of treatment, an average of 7±1 days in patients |
| Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score | Change in Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score. Between 0 and 8 in symptoms questions the score don't mean GERD, more than 8 mean GERD or severe GERD if in impact questions the score is more than 2. | At the beginning and at the end of treatment, an average of 7±1 days in patients |
| Number of Participants With Adverse Events | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | From the beginning to the end of treatment, an average of 7±1 days in patients |
| Degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product | Assessment of degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product using 5-point Likert scales (0=very dissatisfied, 1=dissatisfied, 2=indifferent, 3=satisfied, 4=very satisfied). | Through study completion, an average of 6 months |
| Mean intragastric pH | Change in mean intragastric pH for 20 minutes before and after product intake | Baseline visit |
| Number of episodes of GER (intraoesophageal pH < 4) | Change in the number of episodes of GER (intraoesophageal pH < 4). Evaluation 20 minutes before and after taking the product | Baseline visit |
| Time with oesophageal pH < 4 | Change in the time with oesophageal pH < 4. Evaluation 20 minutes before and after taking the product | Baseline visit |
| Longest reflux episode (oesophageal pH <4) | Change in the time of longest reflux episode (oesophageal pH <4). Evaluation 20 minutes before and after taking the product | Baseline visit |
| D004066 | Digestive System Diseases |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |